
    
      Given no specific antiviral therapies for new coronavirus pneumonia approved yet and Ganovo,
      an oral Hepatitis C virus protease inhibitor, approved in China in June 2018 , this open,
      controlled trial will evaluate the efficacy and safety of Ganovo in hospitalized patients
      infected with SARS-CoV-2.
    
  